HRP20250516T1 - Pripravak koji sadrži roginolisib i režim za doziranje u liječenju raka ili upalne ili autoimune bolesti - Google Patents

Pripravak koji sadrži roginolisib i režim za doziranje u liječenju raka ili upalne ili autoimune bolesti Download PDF

Info

Publication number
HRP20250516T1
HRP20250516T1 HRP20250516TT HRP20250516T HRP20250516T1 HR P20250516 T1 HRP20250516 T1 HR P20250516T1 HR P20250516T T HRP20250516T T HR P20250516TT HR P20250516 T HRP20250516 T HR P20250516T HR P20250516 T1 HRP20250516 T1 HR P20250516T1
Authority
HR
Croatia
Prior art keywords
salt
cancer
compound
formula
disease
Prior art date
Application number
HRP20250516TT
Other languages
English (en)
Croatian (hr)
Inventor
Catherine PICKERING
Lars Van Der Veen
Michael LAHN
Rebeca ZORRILLA
Zoë JOHNSON
Original Assignee
Ionctura Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104416.9A external-priority patent/GB202104416D0/en
Priority claimed from GBGB2117511.2A external-priority patent/GB202117511D0/en
Application filed by Ionctura Sa filed Critical Ionctura Sa
Publication of HRP20250516T1 publication Critical patent/HRP20250516T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
HRP20250516TT 2021-03-29 2022-03-29 Pripravak koji sadrži roginolisib i režim za doziranje u liječenju raka ili upalne ili autoimune bolesti HRP20250516T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2104416.9A GB202104416D0 (en) 2021-03-29 2021-03-29 Treatment reginmens
GBGB2117511.2A GB202117511D0 (en) 2021-12-03 2021-12-03 Treatment regimens
EP22719266.3A EP4313058B1 (en) 2021-03-29 2022-03-29 Composition comprising roginolisib and dosage regime for treating cancer or an inflammatory or autoimmune disease
PCT/EP2022/058283 WO2022207646A1 (en) 2021-03-29 2022-03-29 A pi3k-delta inhibitor for use in treatment regimens

Publications (1)

Publication Number Publication Date
HRP20250516T1 true HRP20250516T1 (hr) 2025-06-20

Family

ID=81388915

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20250516TT HRP20250516T1 (hr) 2021-03-29 2022-03-29 Pripravak koji sadrži roginolisib i režim za doziranje u liječenju raka ili upalne ili autoimune bolesti

Country Status (17)

Country Link
US (1) US12605389B2 (https=)
EP (1) EP4313058B1 (https=)
JP (1) JP7839803B2 (https=)
AU (1) AU2022251843B2 (https=)
CA (1) CA3212731A1 (https=)
DK (1) DK4313058T3 (https=)
ES (1) ES3031295T3 (https=)
FI (1) FI4313058T3 (https=)
HR (1) HRP20250516T1 (https=)
HU (1) HUE071610T2 (https=)
LT (1) LT4313058T (https=)
MX (1) MX2023011442A (https=)
PL (1) PL4313058T3 (https=)
PT (1) PT4313058T (https=)
RS (1) RS66754B1 (https=)
SI (1) SI4313058T1 (https=)
WO (1) WO2022207646A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026510567A (ja) * 2023-03-03 2026-04-08 アイオンクチュラ・ソシエテ・アノニム 血液悪性腫瘍の治療におけるロギノリシブ及びbcl-2阻害剤の組み合わせ
AU2024231699A1 (en) * 2023-03-03 2025-09-11 Ionctura Sa Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201290305A1 (ru) 2009-11-13 2012-12-28 Мерк Сероно С.А. Производные трициклического пиразоламина
WO2014121901A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
US9986723B2 (en) 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma

Also Published As

Publication number Publication date
PT4313058T (pt) 2025-06-02
AU2022251843A1 (en) 2023-10-05
LT4313058T (lt) 2025-05-26
US20240058351A1 (en) 2024-02-22
RS66754B1 (sr) 2025-05-30
WO2022207646A1 (en) 2022-10-06
JP2024518685A (ja) 2024-05-02
US12605389B2 (en) 2026-04-21
PL4313058T3 (pl) 2025-06-23
AU2022251843B2 (en) 2026-04-09
HUE071610T2 (hu) 2025-09-28
EP4313058A1 (en) 2024-02-07
ES3031295T3 (en) 2025-07-07
CA3212731A1 (en) 2022-10-06
SI4313058T1 (sl) 2025-07-31
EP4313058B1 (en) 2025-03-05
FI4313058T3 (fi) 2025-04-30
MX2023011442A (es) 2023-10-18
JP7839803B2 (ja) 2026-04-02
DK4313058T3 (da) 2025-05-12

Similar Documents

Publication Publication Date Title
HRP20250516T1 (hr) Pripravak koji sadrži roginolisib i režim za doziranje u liječenju raka ili upalne ili autoimune bolesti
US11225486B2 (en) Tertiary alcohols as PI3K-γ inhibitors
HRP20230379T1 (hr) TETRAHIDROPIRANIL AMINO-PIROLOPIRIMIDINON ZA PRIMJENU U LIJEČENJU POREMEĆAJA POSREDOVANIH BTK-om
HRP20220362T1 (hr) Biciklički kondenzirani heteroarilni ili arilni spojevi i njihova upotreba kao inhibitori irak4
AU2015215045A1 (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HRP20110097T1 (hr) Derivati fenilpirazola kao nesteroidni ligandi glukokortikoidnih receptora
US12269813B2 (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate
JP2021505575A5 (https=)
JP2021505575A (ja) 非ラセミ混合物およびその使用
JP2018531288A5 (https=)
JP2018529742A5 (https=)
US11046658B2 (en) Aminopyrazine derivatives as PI3K-γ inhibitors
JP2024518685A5 (https=)
JP2024509828A (ja) Malt1阻害剤及びbtk阻害剤を使用する併用療法
WO2019126505A1 (en) 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
CN102858342B (zh) 用于便秘的芳基乙烯基氮杂环烷烃化合物
RU2017105257A (ru) Соли вольфрама (vi) для применения в лечении инфертильности, для поддержания нормальной репродуктивной функции и фертильности у недиабетической самки млекопитающего, а также для повышения эффективности вспомогательных репродуктивных технологий
JP2015527396A5 (https=)
US20130317054A1 (en) Neuronal nicotinic agonist and methods of use
HK40116017A (zh) 作为bcl-2抑制剂的化合物
CN107304183A (zh) 吡仑帕奈晶型及其制备方法和用途
WO2025092674A1 (zh) 肠道菌群调节剂在制备预防和/或治疗脑部神经疾病的药物中的用途
EA049371B1 (ru) ТРЕТИЧНЫЕ СПИРТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kg
Gengraf et al. CYCLOSPORINE (CICLOSPORIN)
EA043981B1 (ru) ТРЕТИЧНЫЕ СПИРТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-γ